Literature DB >> 2553123

A naturally occurring molecular form of human plasma cholinesterase is an albumin conjugate.

P Masson1.   

Abstract

Human plasma cholinesterase (acylcholine acylhydrolase, EC 3.1.1.8) consists of four main molecular forms designated as C1, C2, C3 and C4 according to their electrophoretic mobility on gels. The major component, C4, is the tetrameric form; C1 and C3 are the monomeric and dimeric forms, respectively. The C2 form, which has an apparent free electrophoretic mobility higher than that of the three size isomers, and, moreover, a higher isoelectric point, was found to be a covalent conjugate between the cholinesterase monomer and serum albumin. This result is supported by the following arguments: the non-catalytic subunit of C2 was found to be a carbohydrate-free protein of apparent molecular mass 65 kDa that could not be labelled by diisopropylfluorophosphonate in the labelling conditions of esterases. It possesses a high affinity for a long-chain aliphatic ligand (a substituted octadecylamine) and for Cibacron blue F3 GA, and could be adsorbed on an immunoadsorbent for albumin. The two subunits of C2 are disulfide bridge linked; the active center of the cholinesterase subunit is partly masked by the albumin molecule. The conjugation reaction very likely occurs in the hepatic cell and not in plasma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553123     DOI: 10.1016/0167-4838(89)90282-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

1.  The esterase-like activity of serum albumin may be due to cholinesterase contamination.

Authors:  N Chapuis; C Brühlmann; M Reist; P A Carrupt; J M Mayer; B Testa
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

2.  Monoclonal antibodies to human butyrylcholinesterase reactive with butyrylcholinesterase in animal plasma.

Authors:  Hong Peng; Stephen Brimijoin; Anna Hrabovska; Eric Krejci; Thomas A Blake; Rudolph C Johnson; Patrick Masson; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2015-11-14       Impact factor: 5.192

3.  Structural and functional investigations of cholinesterases by means of affinity electrophoresis.

Authors:  P Masson
Journal:  Cell Mol Neurobiol       Date:  1991-02       Impact factor: 5.046

4.  Endogenous butyrylcholinesterase in SV40 transformed cell lines: COS-1, COS-7, MRC-5 SV40, and WI-38 VA13.

Authors:  M Kris; O Jbilo; C F Bartels; P Masson; S Rhode; O Lockridge
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-10       Impact factor: 2.416

5.  Butyrylcholinesterase is complexed with transferrin in chicken serum.

Authors:  E Weitnauer; C Ebert; F Hucho; A Robitzki; C Weise; P G Layer
Journal:  J Protein Chem       Date:  1999-02

6.  Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing.

Authors:  B N La Du; C F Bartels; C P Nogueira; M Arpagaus; O Lockridge
Journal:  Cell Mol Neurobiol       Date:  1991-02       Impact factor: 5.046

7.  Butyrylcholinesterase-Mediated enhancement of the enzymatic activity of trypsin.

Authors:  S Darvesh; R Kumar; S Roberts; R Walsh; E Martin
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

8.  Effects of physical exercise on butyrylcholinesterase in obese adolescents.

Authors:  Isabela M W Silva; Neiva Leite; Dellyana Boberg; Thais J Chaves; Gerusa M Eisfeld; Gisele M Eisfeld; Gleyse F Bono; Ricardo L R Souza; Lupe Furtado-Alle
Journal:  Genet Mol Biol       Date:  2012-10-09       Impact factor: 1.771

9.  Molecular forms of butyrylcholinesterase and obesity.

Authors:  Dellyana R Boberg; Lupe Furtado-Alle; Ricardo L R Souza; Eleidi A Chautard-Freire-Maia
Journal:  Genet Mol Biol       Date:  2010-09-01       Impact factor: 1.771

10.  Arylesterase phenotype-specific positive association between arylesterase activity and cholinesterase specific activity in human serum.

Authors:  Yutaka Aoki; Kathy J Helzlsouer; Paul T Strickland
Journal:  Int J Environ Res Public Health       Date:  2014-01-27       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.